Evaluating the effect of Doxycycline on biomarkers of oxidative stress in patients with ischemic stroke: a randomized clinical trial study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170114031921N6

Enrollment

Registered

2024-02-24

Start date

2024-02-29

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke. Family history of stroke

Interventions

Intervention group: 100 mg doxycycline every 12 hours for 7 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinical diagnosis of acute hemispheric ischemic stroke Focal neurological disorder MRI and CT radiological findings consistent with the clinical diagnosis of acute hemispheric stroke Absence of other concurrent inflammatory disease

Exclusion criteria

Exclusion criteria: Available evidence based on acute or chronic intracerebral hemorrhage and cerebral aneurysm Drug intolerance and side effects

Design outcomes

Primary

Measure	Time frame
Malone dialdehyde. Timepoint: One day before starting doxycycline treatment and 7 days after treatment. Method of measurement: It is checked by using ELISA Reed kits and reading the wavelength by variable spectrophotometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfereshteh mehri

Hamedan University of Medical Sciences

Freshteh_mehri@yahoo.com+98 910 679 4733

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026